Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour

NCT ID: NCT03593226

Last Updated: 2025-02-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-11-30
• Study Completion Date: 2023-12-31

Brief Summary

This study will evaluate if AGI-134 given alone is safe and tolerate in treating patients with unresectable/metastatic solid tumours.

Detailed Description

Study AGI-134.FIM.101 was a Phase I/IIa, first in man (FIM), multi-center, single-arm, open-label study, designed to evaluate the safety and tolerability of escalating doses of AGI-134 as a monotherapy in unresectable/metastatic solid tumors.

The study comprised of 2 parts:

Part 1 was an accelerated escalation of the AGI-134 dose, designed to assess the safety and tolerability of AGI-134, as well as to determine the MTD (maximum tolerated dose) and recommended dose for Part 2 of the study (RP2D).

Part 2 was designed to assess the safety, tolerability and biological activity of AGI-134 at the RP2D in subjects with either deep or superficial unresectable/metastatic solid tumors.

Conditions

Superficial, Palpable, Unresectable/Metastatic Solid Tumour

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AGI-134 25 mg

25 mg AGI-134 (1 mL) via intratumor injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.

Group Type: EXPERIMENTAL

AGI-134

Intervention Type: DRUG

AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.

AGI-134 50 mg

50 mg AGI-134 (2 mL) via intratumor injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.

Group Type: EXPERIMENTAL

AGI-134

Intervention Type: DRUG

AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.

AGI-134 100 mg

100 mg AGI-134 (4 mL) via intratumor injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.

Group Type: EXPERIMENTAL

AGI-134

Intervention Type: DRUG

AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.

AGI-134 200 mg

200 mg AGI-134 (8 mL) via intratumor injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.

Group Type: EXPERIMENTAL

AGI-134

Intervention Type: DRUG

AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.

Interventions

AGI-134

AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Adult male or female aged 18 years old or older.

2. Have a histologically or cytologically confirmed unresectable metastatic solid tumour and who have received or been intolerant to all curative treatment options and treatments demonstrated to prolong survival.

3. Subjects should have at least two measurable lesions based on RECIST v1.1 as determined by the site study team.

4. Subjects who are willing to undergo tumour biopsies, unless tumour is considered inaccessible or biopsy is otherwise considered not in the subject's best interest.

5. With sufficient tumour size for IT injection

6. Has ≥ 2 lesions:

Has ≥1 injectable lesion which is amenable to injection and biopsy and is measurable according to RECIST v1.1.

Has ≥1 metastatic lesion is amenable for biopsy and measurable according to RECIST v1.1

7. Evaluable Disease according to RECIST v1.1

8. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

9. Has a life expectancy >3 months

10. Adequate organ function

11. Women of childbearing potential and all men must agree to use 2 methods of an adequate contraception

12. Subject is able and willing to comply with the requirements of the protocol.

13. Subject is able to voluntarily provide written informed consent.

Exclusion Criteria

1. Has a disease that is suitable for therapy administered with curative intent.

2. Has any active, acute, or chronic infection(s) that are uncontrolled and/or requiring treatment, such as antibiotics

3. An active autoimmune disease that has required systemic treatment in the 2 years preceding the study

4. History of or plan for splenectomy or splenic irradiation

5. History of organ transplant or currently taking active immunosuppressive therapy

6. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)

7. Has known active or chronic Hepatitis B or Hepatitis C

8. History or evidence of cancer associated with immunodeficiency states

9. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

10. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment

11. Is expected to require any other form of antineoplastic therapy while on study

12. Had received live vaccines within 30 days prior to the first dose of trial treatment.

13. Has positive Immunoglobulin E (IgE) anti -Gal

14. Subject has a known allergy to alpha-Gal, such as red meat allergy, exposure to lone star tick (Amblyomma americanum), Ixodes ricinus/ holocyclus, or Cetuximab allergy

15. Has known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product

16. History or evidence of central nervous system metastases and/or carcinomatous meningitis (unless stable without treatment for at least 6 weeks and not requiring steroids)

17. Has received other experimental therapies or used an investigational device within 28 days of the first dose of treatment

18. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 14 days prior to study Day 1 or has not recovered from Adverse Event (AE) ≤ Grade 1 by treatment administered more than 14 days before first dose

19. Has had a prior anti-cancer monoclonal antibody (mAb) within 28 days prior to study Day 1 or who has not recovered from AE ≤ Grade 1 by treatment administered more than 28 days earlier.

20. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.

21. Has unstable angina, new onset angina within the last 3 months, myocardial infarction within the last 6 months, uncontrolled atrial fibrillation, or current congestive heart failure with New York Heart Association Class III or higher.

22. Has a known current additional malignancy that is progressing or requires active treatment

23. O2 saturation < 92% (on room air).

24. Has an underlying medical condition that would preclude study participation or other psychological, social or physical examination finding or a laboratory abnormality that the Investigator considers would make the subject a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results.

25. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Agalimmune Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

UCLA

Los Angeles, California, United States

AHS Hospital Corp.

Morristown, New Jersey, United States

Providence Cancer Institute Franz Clinic

Portland, Oregon, United States

Emek Medical Center

Afula, , Israel

Rambam Health Care Campus

Haifa, , Israel

Hadassah Hebrew University Medical Center

Jerusalem, , Israel

Sheba Medical Center

Ramat Gan, , Israel

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

University of Birmingham

Birmingham, , United Kingdom

Edinburgh Cancer Research Centre

Edinburgh, , United Kingdom

The Beatson West of Scotland Cancer Centre

Glasgow, , United Kingdom

University Collage London

London, , United Kingdom

The Christie NHS Foundation Trust

Manchester, , United Kingdom

Churchill Hospital

Oxford, , United Kingdom

Countries

United States; Israel; United Kingdom

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

AGI-134.FIM.101

Identifier Type: -

Identifier Source: org_study_id